Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: -1.60 (-1.31%)
Spread: 0.40 (0.333%)
Open: 120.20
High: 121.60
Low: 120.20
Prev. Close: 122.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

Thu, 04th Mar 2021 12:46

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Origin Enterprises PLC - Dublin-based agri-services provider - Revenue for six months to end of January falls to EUR572.4 million from EUR604.9 million, though pretax loss slims to EUR2.5 million from EUR7.2 million. "Operating profit of EUR1.2 million in the period compared favourably to a loss of EUR2.8 million in H1 2020. This was largely as a result of a more normalised cropping profile across the group, set against last year's highly unseasonal and prolonged weather conditions which materially impacted business performance in H1 2020," says Chief Executive Sean Coyle. Says first half performance sets "positive foundation" for full-year, though uncertainties remain heading into the seasonally more important second half. Says well-placed to deliver "good" growth in earnings for full-year.

----------

Amryt Pharma PLC - London-based biopharmaceutical company - Reports 19% growth in 2020 revenue to USD182.6 million, though pretax loss widens to USD105.9 million from USD63.5 million. Selling, general and administrative expenses more than double to USD76.7 million from USD35.5 million. "Our business continues to perform and grow strongly. In particular, our revenue growth exceeded expectations and the fact that we turned Ebitda profitable has translated into a significant increase in our cash balances. Given the strong performance of our business in 2020, we are now issuing revenue guidance for FY 2021 of [between USD200 million and USD205 million] which demonstrates our confidence in Amryt's prospects," says Chief Executive Joe Wiley.

----------

Hutchison China Meditech Ltd - China-based biopharmaceutical company - Total revenue for 2020 USD228.0 million, up from USD204.9 million the year before. Net loss widens to USD115.5 million from USD103.7 million. Guides to Oncology/Immunology consolidated revenue of USD110 million toUSD130 million, versus USD30.2 million in 2020. Adds it intends to seek shareholder approval to change it name to Hutchmed China Ltd to its forthcoming annual general meeting. "Over the next three years, we will continue to grow our R&D and commercial organizations globally to support the anticipated launch of our oncology drugs in China, the US and Europe," says Chair Simon To.

----------

Syncona Ltd - investor in life science companies - Notes portfolio company, Autolus Therapeutics PLC, reports net loss of USD142.1 million for 2020, wider than USD123.8 million in 2019. "Autolus' primary focus is on delivering the potential pivotal Auto1 program and the company starts 2021 in a position of financial strength, having raised a total of USD131 million in gross proceeds this quarter, giving us a cash runway into the first half of 2023," says Christian Itin, chair and chief executive of Autolus.

----------

Cairn Homes PLC - Irish homebuilding company - Revenue for 2020 slumps to EUR261.9 million from EUR435.3 million in 2019, while pretax profit drops over 100% to EUR14.8 million from EUR58.6 million. Says current closed and forward order book of new homes underpins growth for 2021 with an underlying margin "comfortably higher" than reported margin in 2020. 2020 operating margin weakened to 9.3% from 15.6%. "Our construction sites have been closed since the start of the year and assuming they fully reopen on 6 April 2021, Cairn's construction activities will be limited to just over 8 months in the current year. This will have an impact on the number of new homes which we will be able to build and sell in 2021," company says.

----------

Pacific Horizon Investment Trust PLC - invests in Asia-Pacific region excluding Japan and Indian sub-continent - Reports net asset value per share of 699.01 pence at end of January, up 45% from 481.92p at July-end. NAV per share total return 45% while share price total return was 53% as the premium increased to 10% from 4.6%. Over the same period the MSCI All Country Asia ex Japan Index's total return was 21% in sterling terms. "Our holdings outperformed in most regions. At the index level, Materials was the best performing sector, up 70.0%, followed by Consumer Discretionary up 49.5% and Communications Services up 48.7%. The worst were Information Technology, up 34.6%, Industrials up 22.6% and Energy up 5.7%," firm says.

----------

Mid Wynd International Investment Trust PLC - looks to invest in high quality companies, with proven profitability and high levels of cash generation - Net asset value per share at December 31 698.66p, up 14% from 612.61p at June 30 and 581.10p at end of 2019. For six months to end of December, company's share price rose 18% on a total return basis with dividends assumed to be re-investment, while NAV per share rose 15% on total return basis. This compares to a total return from the MSCI All Country World Index (GBP) of 12%. "Although we have outperformed our comparator index, which is of course pleasing, this outperformance would have been greater had we held Tesla and more Apple shares in line with the index," firm notes.

----------

Hansard Global PLC - specialist long-term savings provider - Says new business levels GBP76.3 million for half-year to December 31 on a present value of new business premiums basis, down 4.7% on a year ago. Pretax profit up 12% to GBP2.9 million from GBP2.6 million year-on-year due to lower new business acquisition costs. Declares stable interim dividend of 1.8p per share.

----------

Online Blockchain PLC - holds around 18% stake in investor website operator ADVFN PLC and incubates developers of blockchains and cryptocurrencies - Revenue for six months to December 31 GBP56,000, increasing 27% from GBP44,000 a year ago, while pretax loss slims to GBP76,000 from GBP144,000. Says it is excited for prospects for blockchain, "irrespective" of the value of bitcoin in 2021. Notes that ADVFN PLC, its largest asset, reports revenue of GBP4.2 million over the same period, up from GBPP3.7 million a year ago.

----------

Crystal Amber Fund Ltd - activist fund investing in small and mid-cap UK equities - Net asset value per share grew 22% over the six months to December 31 to 129 pence, versus a 24% increase in Numis Small Cap Index. "The period under review saw ongoing uncertainty from the Covid-19 pandemic, as well as final Brexit negotiations. The latter adversely affected the appetite of global investors for UK stocks, specifically small and medium sized companies, as well as the appetite of corporate acquirers for attractively priced targets," firm says, adding that this has left many UK companies undervalued by international standards and if the UK's rapid vaccination programme does translate into earlier economic recovery, there should be a re-rating.

----------

ThinkSmart Ltd - specialist digital payments business - Total revenue for six months to December 31 GBP2.4 million from GBP3.3 million, though pretax profit jumps to GBP53.7 million from GBP16.0 million after recording GBP52.9 million gain on financial instruments versus GBP16.6 million a year ago. "While our strategic efforts are focused on further value creation for shareholders via our holding in Clearpay, the managed wind down of our legacy operations continues to generate positive cash flow as we control costs while rightsizing the operations to lower volumes. This leaves our balance sheet robust. There is inherent, tangible value within our proprietary payments technology and we are continuing to consider how best to optimise the value of this asset," Executive Chair Ned Montarello says.

----------

Manx Financial Group PLC - Isle of Man-based financial services firm - Net interest income for 2020 GBP15.5 million, down from GBP17.9 million in 2019. Net trading income edges down 3.7% to GBP15.4 million from GBP16.0 million. Pretax loss falls 33% to GBP2.0 million from GBP3.0 million, with impairments on loans and advances to customers rising to GBP4.0 million from GBP1.9 million. "The Isle of Man has successfully bounced back from lockdowns, as shown by the less than expected uptake in the government support schemes, our positive lending figures and the encouraging recent government budget. As such, I expect a continued improvement in the economy on Island which will, in turn, create a positive environment for our lending and wealth management businesses to operate within," company says.

----------

Franchise Brands PLC - Macclesfield-based multi-brand franchise business - Reports revenue of GBP49.3 million for 2020, up 12% on 2019's GBP44.0 million. Pretax profit rises 12% to GBP3.7 million from GBP3.3 million. "Resilient performance following strong growth in Q1, early and decisive action taken during the Spring lockdown to reduce costs, and a strong recovery across the majority of businesses during the second half of the year," company says. Proposes final dividend for 2020 of 0.8p per share, up from 0.65p in 2019, to give total payout of 1.1p, up 16%. Says trading has started strongly in 2021, with resilient sales in the B2B division and robust recruitment in the B2C division.

----------

Airea PLC - West Yorkshire-based floor coverings manufacturer - Revenue for 2020 falls 24% to GBP14.6 million from GBP19.2 million in 2019, while pretax profit dives to GBP500,000 from GBP2.0 million. Says after strong start in first quarter, the pandemic hit the group's ability to trade. "Whilst the group remained open for business throughout the year management had to reassess its strategic priorities and made the decision to prioritise cash and working capital to provide the best defence against uncertainty," company says.

----------

MediaZest PLC - London-based audio visual services firm - Reports revenue of GBP3.1 million for eighteen months to September 30 versus GBP3.3 million in the twelve months to March 31, 2019. Swings to pretax loss of GBP478,000 from GBP6,000 profit. Says results for eighteen month period hit by pandemic, with a significant reduction in revenue particularly during the first UK lockdown. "At this time, it remains difficult to fully assess the extent to which the Pandemic will affect the group's forthcoming trading and financial performance as the situation continues to evolve. The second national lockdown in November 2020 and closure of many retail businesses had an impact, however new project pitches have increased in number since the start of 2021, despite the third national lockdown coming into effect," Mediazest says. Firm working on the assumption that the disruption caused by the pandemic will have an impact "deep" into 2021.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
14 Nov 2023 11:29

IN BRIEF: Syncona notes investee company's quarterly loss

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.

Read more
9 Nov 2023 15:44

UK earnings, trading statements calendar - next 7 days

Friday 10 November 
Allianz Technology Trust PLCQ3 Results
Wheaton Precious Metals CorpQ3 Results
Monday 13 November 
Bank of Cyprus Holdings PLCQ3 Results
British Land Co PLCHalf Year Results
Kainos Group PLCHalf Year Results
Team Internet Group PLCQ3 Results
Tuesday 14 November 
ActiveOps PLCHalf Year Results
Babcock International Group PLCHalf Year Results
Bank of Georgia Group PLCQ3 Results
Castings PLCHalf Year Results
ConvaTec Group PLCTrading Statement
DCC PLCHalf Year Results
Forterra PLCHalf Year Results
Gear4Music PLCHalf Year Results
Genel Energy PLCTrading Statement
HydrogenOne Capital Growth PLCQ3 Results
Hill & Smith PLCTrading Statement
Imperial Brands PLCFull Year Results
Informa PLCTrading Statement
Land Securities Group PLCHalf Year Results
Oxford Instruments PLCHalf Year Results
Picton Property Income LtdHalf Year Results
Renalytix PLCQ1 Results
Vesuvius PLCTrading Statement
Vodafone Group PLCHalf Year Results
Wise PLCHalf Year Results
Wednesday 15 November 
Diversified Energy Co PLCTrading Statement
Experian PLCHalf Year Results
Fuller, Smith & Turner PLCHalf Year Results
Genuit Group PLCTrading Statement
Intermediate Capital Group PLCHalf Year Results
Ninety One PLC and LtdHalf Year Results
Renold PLCHalf Year Results
SSE PLCHalf Year Results
Synthomer PLCTrading Statement
Tracsis PLCFull Year Results
Tullow Oil PLCTrading Statement
Warehouse REIT PLCHalf Year Results
Thursday 16 November 
Assura PLCHalf Year Results
Atalaya Mining PLCQ3 Results
Aviva PLCTrading Statement
Burberry Group PLCHalf Year Results
Close Brothers Group PLCTrading Statement
CMC Markets PLCHalf Year Results
Crest Nicholson Holdings PLCTrading Statement
Halma PLCHalf Year Results
Great Portland Estates PLCHalf Year Results
Kier Group PLCTrading Statement
International Distributions Services PLCHalf Year Results
Investec PLC and LtdHalf Year Results
Liontrust Asset Management PLCHalf Year Results
Manolete Partners PLCHalf Year Results
Melrose Industries PLCTrading Statement
Norcros PLCHalf Year Results
Premier Foods PLCHalf Year Results
Qinetiq Group PLCHalf Year Results
Spirax-Sarco Engineering PLCTrading Statement
Syncona LtdHalf Year Results
Tatton Asset Management PLCHalf Year Results
Tyman PLCTrading Statement
United Utlities Group PLCHalf Year Results
Young & Co's Brewery PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Nov 2023 11:51

TRADING UPDATES: Augmentum Fintech makes further investment in Tide

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
18 Oct 2023 12:01

IN BRIEF: Syncona announces takeover offer for Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline Therapeutic Holdings PLC. Offers upfront cash consideration of USD5.00 per American depository share, representing a 20% premium over the USD4.16 volume weighted average price from October 4 to October 16. Syncona currently owns around 57.9% of shares in Stevenage, England-based Freeline, which it co-founded in 2015. Freeline aims to develop gene therapies to treat chronic diseases, most notably its potentially "transformative" FLT201 programme to treat Gaucher disease.

Read more
4 Oct 2023 14:28

Syncona says Freeline and SwanBio clinical trails make progress

(Alliance News) - Syncona Ltd on Wednesday said its portfolio company Freeline Therapeutics Holdings PLC has received positive initial safety, tolerability and enzyme activity data from its FLT201 trial for the treatment of Gaucher disease.

Read more
29 Sep 2023 09:51

IN BRIEF: Syncona launches GBP40 million share buyback programme

Syncona Ltd - London-based investor in healthcare companies - Launches share buyback programme worth up to GBP40.0 million, to be conducted by Numis Securities Ltd. Says core focus remains on allocating capital to portfolio companies' assets. However the buyback is necessary due to Syncona's shares currently trading at a discount to net asset value, which was 184.6 pence per share at June 30. Says buyback will not affect investments into clinical stage assets planned for the next 24 months. Company expects that capital deployment into portfolio and pipeline will total between GBP150 million and GBP200 million for the year ending March 31, in line with prior guidance. Chair Melanie Gee says Syncona "has a high level of confidence in our portfolio and its valuation".

Read more
11 Sep 2023 15:42

Syncona shares slump as Novartis ends eye treatment development

(Sharecast News) - Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of £54.5m for Gyroscope Holdings in which Syncona once held a 54% stake.

Read more
11 Sep 2023 09:51

Syncona suffers negative valuation hit as Novartis discontinues GT005

(Alliance News) - Syncona Ltd on Monday said it has been informed by Swiss-American pharmaceutical company Novartis AG that the development of eye treatment, GT005, for geographic atrophy secondary to dry age-related macular degeneration will be discontinued.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
15 Aug 2023 13:56

IN BRIEF: Syncona notes clinical progress of portfolio firm Freeline

Syncona Ltd - London-based healthcare investor - Notes second quarter results announcement from its Nasdaq-listed portfolio company Freeline Therapeutics Holdings PLC. Says the key highlights include Freeline completing the dosing in the first dose cohort of the phase 1/2 trial of FLT201 in Gaucher disease, following dosing of the second patient. Says initial clinical data from the FLT201 trial is expected in the second half of 2023. Also says Freeline has a cash position of USD38.8 million at June 30 compared to USD55.4 million on March 31, which Freeline expects will enable the company to fund its planned operations into the second quarter of 2024. Freeline says net income in the three months that ended June 30 narrowed to USD14.8 million from USD51.1 million a year earlier.

Read more
10 Aug 2023 09:33

IN BRIEF: Syncona says net asset value slips 1% in first quarter

Syncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona's financial first quarter. Notes performance was hurt by "negative foreign exchange movements" across its life science portfolio. This is valued at GBP628.7 million on June 30, up 4.0% from GBP604.6 million on March 31.

Read more
10 Aug 2023 08:34

Syncona reports slight dip in net assets

(Sharecast News) - Healthcare investor Syncona reported a slight dip in net assets in its quarterly update on Thursday, to £1.24bn, down from £1.26bn at the end of March.

Read more
4 Aug 2023 14:09

IN BRIEF: Syncona's portfolio Achilles Therapeutics net loss narrows

Syncona Ltd - Healthcare company focused on developing its life science portfolio - Notes its portfolio company Archilles Therapeutics PLC's net loss in its second quarter ended June 30 narrows 2.9% to USD16.8 million, from USD17.3 million year-on-year. Cash and cash equivalents are "strong", standing at USD143.7 million on June 30, down 17% from USD173.3 million on December 31. Research & development expenses increase are USD13.8 million, down 6.8% from USD14.8 million at the same point the year prior. Archilles Therapeutics's general & administrative expenses were USD4.3 million, down 26% from USD5.8 million the year before, driven by a change in cost allocations and lower professional fees.

Read more
25 Jul 2023 15:47

UK shareholder meetings calendar - next 7 days

Wednesday 26 July 
Aquila Services Group PLCAGM
Blackstone Loan Financing LtdAGM
BP Marsh & Partners PLCAGM
Eurasia Mining PLCAGM
Molten VenturesAGM
Motorpoint Group PLCAGM
NewRiver REIT PLCAGM
Ninety One PLC and LtdAGM
Norcros PLCAGM
Oracle Power PLCAGM
Palace Capital PLCAGM
ProBiotix Health PLCAGM
Seeen PLCAGM
Silverwood Brands PLCAGM
Triad Group PLCAGM
Water Intelligence PLCAGM
Zephyr Energy PLCAGM
Thursday 27 July 
Foresight Group Holdings LtdAGM
Marks Electrical Group PLCAGM
Silver Bullet Data Services Group PLCAGM
Friday 28 July 
African Pioneer PLCAGM
Bezant Resources PLCAGM
Braveheart Investment Group PLCAGM
Cordiant Digital Infrastructure LtdAGM
DP Poland PLCAGM
Intuitive Investments Group PLCGM re proposals on investment strategy
Jangada Mines PLCAGM
Mercantile Ports & Logistics LtdAGM
MetalNRG PLCAGM
Northern 2 VCT PLCGM re party transaction
Polymetal International PLCGM re delisting
R&Q Insurance Holdings LtdAGM
Science in Sport PLCAGM
Urban Logistics REIT PLCAGM
Xtract Resources PLCAGM
Monday 31 July 
B90 Holdings PLCAGM
Barryroe Offshore Energy PLCEGM re proposed cancellation of admission to trading on AIM
Live Co Group PLCAGM
OnTheMarket PLCAGM
Tintra PLCAGM
Tuesday 1 August 
Bonhill Group PLCGM re members' voluntary liquidation
Deltex Medical Group PLCGM re placing and subscription
Syncona LtdAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
15 Jun 2023 08:44

Syncona net asset value falls as cites economic uncertainty, inflation

(Alliance News) - Syncona Ltd on Thursday reported a lower net asset value per share at the end of March amid a "challenging" backdrop for the biotechnology companies, citing inflation and economic uncertainty.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.